The specific knowledge of the different molecules, pharmacologic and physiochemical characteristics for each biologic botulinum toxin type A (BoNTA) product, available in our chain of drug suppliers, is essential to ensure an adequate prescription with a minimum of adverse events. The BoNTA is prescribed in several clinical conditions that are authorized by official organizations such as FDA (Food Drugs Administration) in the USA, the EMA (European Medicine Agency) in Europe and INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) in Colombia. Comparing the general characteristics of the available different BoNTA products, is understandable that they are similar biological entities, not identical, with different potency, which determine an efficacy profile, and specific security for each product. For that reason they are non-interchangeable products, and its clinical use must be tailored to the patient’s clinical condition, in addition to the product to be used and the physician’s experience relate to the application method.